Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs) - induced apoptosis

Medical Science Monitor

Volumn 18, Issue 7, 2012, Pages

  Zhan, Yi ^a   Sun, Hui lin ^a   Chen, Hong ^a   Zhang, Hua ^a   Sun, Jia ^a   Zhang, Zhen ^a   Cai, De hong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Apoptosis; Bcl 2; Diabetes; Endothelium; Peptide glucagon like peptide 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CASPASE 3; CASPASE 9; CYTOCHROME C; GLUCAGON LIKE PEPTIDE 1; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 84863787414     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883207     Document Type: Article

References (36)

1. Yamagishi S, Imaizumi T: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des, 2005; 11: 2279-99
2. Meerwaldt R, van der Vaart MG, van Dam GM et al: Clinical Relevance of Advanced Glycation Endproducts for Vascular Surgery. Eur J Vasc Endovasc, 2008; 36: 125-31
3. Warboys CM, Toh HB, Fraser PA: Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci, 2009; 50: 1319-28
4. Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol, 2011; 46: 217-24
5. Jakus V, Rietbrock N: Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res, 2004; 53: 131-42
6. Zhou YJ, Wang JH, Zhang J: Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem Biophys Res Commun, 2006; 344: 658-66
7. Vasan S, Foiles P, Founds H: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys, 2003; 419: 89-96
8. Kim W, Egan JM: The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev, 2008; 60: 470-512
9. Aaboe K, Krarup T, Madsbad S, Holst JJ: GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab, 2008; 10: 994-1003
10. Nystrom T: The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res, 2008; 40: 593-606
11. Nystrom T, Gutniak MK, Zhang QM et al: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol-Endoc M, 2004; 287: E1209-15
12. Erdogdu O, Nathanson D, Sjoholm A et al: Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol, 2010; 325: 26-35
13. Xiao-Yun X, Zhao-Hui M, Ke C et al: Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit, 2011; 17(2): BR35-41
14. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S: Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced upregulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun, 2010; 391: 1405-8
15. Oeseburg H, de Boer RA, Buikema H et al: Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol, 2010; 30: 1407-14
16. Puddu A, Storace D, Durante A et al: Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Biochem Biophys Res Commun, 2010; 398: 462-66
17. Cunha DA, Ladriere L, Ortis F et al: Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes, 2009; 58: 2851-62
18. Blandino-Rosano M, Perez-Arana G et al: Aguilar-Diosdado M. Antiproliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol, 2008; 41: 35-44
19. Tews D, Lehr S, Hartwig S et al: Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res, 2009; 41: 294-301
20. Liu JH, Yin F, Guo LX et al: Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin, 2009; 30: 159-65
21. Kimura R, Okouchi M, Fujioka H et al: Glucagon-like peptide-1 (GLP1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience, 2009; 162: 1212-19
22. Poornima I, Brown SB, Bhashyam S et al: Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail, 2008; 1: 153-60
23. Ravassa S, Zudaire A, Carr RD, Diez J: Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol, 2011; 300: H1361-72
24. Marzioni M, Alpini G, Saccomanno S et al: Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut, 2009; 58: 990-97
25. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest, 1973; 52: 2745-56
26. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem, 1991; 266: 7329-32
27. Han Y, Liu Y, Mi Q et al: Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. Int J Vitam Nutr Res, 2010; 80: 168-77
28. Xu B, Chibber R, Ruggiero D et al: Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. Faseb J, 2003; 17: 1289-91
29. Goyal S, Kumar S, Bijjem KV, Singh M: Role of glucagon-like peptide1 in vascular endothelial dysfunction. Indian J Exp Biol, 2010; 48: 61-69
30. Mendez JD, Xie J, Aguilar-Hernandez M, Mendez-Valenzuela V: Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem, 2010; 341: 33-41
31. Chipuk JE, Green DR: How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol, 2008; 18: 157-64
32. Dejean LM, Ryu SY, Martinez-Caballero S et al: MAC and Bcl-2 family proteins conspire in a deadly plot. Biochim Biophys Acta, 2010; 1797: 1231-38
33. Marsden VS, O'Connor L, O'Reilly LA et al: Apoptosis initiated by Bcl2-regulated caspase activation independently of the cytochrome c/Apaf1/caspase-9 apoptosome. Nature, 2002; 419: 634-37
34. Qin Z, Sun Z, Huang J et al: Mutated recombinant human glucagonlike peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett, 2008; 444: 217-21
35. Natalicchio A, De Stefano F, Orlando MR et al: Exendin-4 prevents cJun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells. Endocrinology, 2010; 151: 2019-29
36. Quoyer J, Longuet C, Broca C et al: GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem, 2010; 285: 1989-2002